LBA81 Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma

J. Tabernero, S-E. Al-Batran, Zev A. Wainberg, K. Muro, D. Molena, E. Van Cutsem, Woo Jin Hyung, L.S. Wyrwicz, D-Y. Oh, Takeshi Omori, M. Moehler, Arinilda Campos Bragagnoli, Gabriel Garbaos, M. Liberman, María Luisa Limón, E.C. Smyth, L-Y. Cheng, Nicola Valeri, Ioannis Xynos, Y. Y. Janjigian